SEARCH:   Advanced

Blood, 1 February 2007, Vol. 109, No. 3, pp. 905-909. Prepublished online as a Blood First Edition Paper on October 3, 2006; DOI 10.1182/blood-2006-04-019901. This Article Full Text (PDF) All Versions of this Article: blood-2006-04-019901v1 109/3/905    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dann, E. J Articles by Epelbaum, R. Search for Related Content PubMed PubMed Citation Articles by Dann, E. J Articles by Epelbaum, R. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 26, 2006 Accepted September 18, 2006 Risk adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high risk Hodgkin lymphoma with no impairment of outcome Eldad J Dann*, Rachel Bar-Shalom, Ada Tamir, Nissim Haim, Menachem Ben-Shachar, Irit Avivi, Tzila Zuckerman, Mark Kirschbaum, Odelia Goor, Diana Libster, Jacob M. Rowe, and Ron Epelbaum Rambam Medical Center, Israel Technion, Israel Institute of Technology, Israel Tel Aviv Sourasky Medical Center, Israel Hadassah Mount Scopus Hospital, Israel * Corresponding author; email: e_dann{at}rambam.health.gov.il. Therapy of Hodgkin disease (HD) is designed to prolong progression-free survival and minimize toxicity. The best regimen to achieve this has not yet been defined. 108 patients with newly diagnosed HD and adverse prognostic factors were prospectively studied between 1999 and 2004. They were assigned to therapy according to defined risk stratification. Patients were defined depending on the International Prognostic Score (IPS). Those with IPS of 3 received 2 cycles of escalated BEACOPP (EB), including bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone. All others received 2 cycles of standard BEACOPP (SB). Subsequent therapy was prospectively assigned following two cycles according to results of early interim GA67 or PET/CT. Following a positive interim scan, 4 cycles of EB were administered, whereas 4 cycles of SB were given to patients with a negative scan. The complete remission rate, the 5-year event-free (EFS) and overall survival (OS) were 97%, 85% and 90% respectively. Relapse or progression occurred in 27% of patients with interim positive PET/CT versus 2.3% of negative scans (p<0.02). Early interim FDG-PET/CT is a useful tool for adjustment of chemotherapy on an individual basis. Similar EFS and OS were observed for patients in both risk groups. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020